Vimarsana
Biggest News Aggregation in the World

Page 20 - Bio Developments News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bio Developments. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bio Developments Today - Breaking & Trending Today

US Department of Defense funds MediWound's non-surgical burn treatment - Vimarsana News

US Department of Defense funds MediWound's non-surgical burn treatment

Biotherapeutics company MediWound has secured an additional $6.7 million in funding from the US Department of Defense to advance its non-surgical burn treatment for the US Army.

The top 5 ADC startups favoured by venture capital investors - Vimarsana News

The top 5 ADC startups favoured by venture capital investors

Antibody-drug conjugates (ADC) are booming in the biotech industry this year with mounting investment and M&A deals. Here are five ADC players that have caught the eye of investors in the last 12 months.

MaaT Pharma: the promise of microbiome therapeutics - Vimarsana News

MaaT Pharma: the promise of microbiome therapeutics

Hervé Affagard is the CEO and co-founder of MaaT Pharma and president of Alliance Promotion Microbiote. We sat down with him to discuss the company's promising lead product for gastrointestinal acute graft-versus-host disease.

Merck's path toward pharmacovigilance transformation - Vimarsana News

Merck's path toward pharmacovigilance transformation

At Veeva R&D and Quality Summit 2023, Bio Pharma Reporter caught up with Courtney Gilbert, senior director, business system management and innovation, PV operations and global process enablement, at Merck.

Samsung Biologics: How to overcome biopharma industry challenges - Vimarsana News

Samsung Biologics: How to overcome biopharma industry challenges

A rising demand for biologics means that biotech companies face a multitude of manufacturing challenges, but also plenty of opportunities. We spoke to Kevin Sharp, senior VP and head of sales at Samsung Biologics, to examine what is driving this demand and how the industry, particularly CDMOs, should respond.